olfactory receptor family 8 subfamily F member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR8F1P profile across patient tissues and cancer cell-line models. OR8F1P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OR8F1P is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, OR8F1P RNA expression shows 7,831 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, STAD, and LIHC as cancer lineages where OR8F1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR8F1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR8F1P survival associations across molecular data types. OR8F1P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR8F1P RNA expression–survival associations across cancer types. High OR8F1P expression shows unfavorable associations in KIRC, THCA, COAD, STAD, LIHC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for OR8F1P RNA expression.
This table summarizes OR8F1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR8F1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR8F1P shows higher tumor expression in STAD. The STAD box plot shows higher OR8F1P RNA expression in tumor versus normal tissue (log2 FC = +0.007, t-test p = .042).
This table shows molecular features associated with OR8F1P in patient tissues and cancer cell lines. In patient samples, OR8F1P shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
